Topcon Healthcare Signs Definitive Agreement to Acquire Toku Inc.
Topcon Healthcare announced it has signed a definitive agreement to acquire Toku, Inc., a San Diego-based artificial intelligence (AI) health technology company.
Financial terms of the deal were not disclosed.
Toku’s platforms—CLAiR, BioAge, and MyKidneyAI—use standard color fundus photographs (retinal images) to deliver real-time assessments of cardiovascular risk, biological aging, and chronic kidney disease. The platforms are powered by one of the world’s largest retinal-image datasets. According to Topcon, these innovations advance Topcon Healthcare’s vision of “Healthcare from the Eye," leveraging oculomics to empower both primary care and eyecare providers with predictive, preventive health insights.
By integrating Toku’s advanced AI algorithms into its connected care ecosystem, Topcon said it aims to make noninvasive, AI-driven risk screening broadly accessible across primary care, eyecare, and telehealth environments. Through its vendor-inclusive digital platform, Harmony, Topcon will deliver scalable, cloud-based AI health assessments from routine retinal imaging—expanding preventive care globally.
This initiative, developed in collaboration with the Alliance for Healthcare from the Eye, seeks to improve population health outcomes, expand access to preventive screening, and reduce overall healthcare costs, Topcon stated. Beyond its direct clinical impact, integrating Toku’s algorithms within Harmony also establishes a regulatory and commercial framework for other innovators to deliver oculomics-based health solutions—accelerating growth across the field.
“Toku was founded on the principle of early disease detection, even before patients develop symptoms,” said Ehsan Vaghefi, PhD, CEO of Toku, Inc. “Becoming part of Topcon Healthcare enables us to realize our mission of delivering heart and kidney health screening at an unprecedented scale—potentially saving lives with each scan worldwide.”
To date, Toku has analyzed more than 4.3 million de-identified retinal images linked to clinical data, fueling predictive models that identify individuals at high risk for serious diseases years before traditional tests—and often before any symptoms appear.
“This partnership accelerates not only regulatory clearances and commercialization of new imaging-based health screening solutions, but also the growth of the broader oculomics field,” added Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “As Toku transforms every eye exam into a comprehensive health assessment, Topcon’s global infrastructure will help deliver scalable, affordable AI diagnostics to clinicians and patients worldwide.”